Navigation Links
Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers
Date:2/5/2009

For more information about PreMD, please visit www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


'/>"/>
SOURCE PreMD Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...an, Nov. 19 /PRNewswire-Asia/ -- ScinoPharm, a lea...edients (APIs), announced that its,Tainan facility...tion from,SafeBridge(R) Consultants, Inc. The Cert...ficiency in the safe handling of potent active,pha...cific laboratories and,production areas used for t...
(Date:11/19/2009)..., Nov. 19 The D e al ...f its Most Admired Corporate Dealmakers for the se...as its Most Admired Dealmaker in pharma/biotech fo... and divestitures since January 2006. ,, Over t...ortfolio with a focus on high-growth, innovation-d...
(Date:11/19/2009)...ational Internet Week of Action ,, SILVER SPRI...S. Food and Drug Administration today completed a ...d the International Internet Week of Action (IIWA)...al products. ,, (Logo: http://www.newscom.com/...ffort, the FDA,s Office of Criminal Investigations...
Breaking Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 1CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 2CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 3BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday July 30 at 5 3A00 p m ET 2823 3A00 CET 29 50515 1BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday July 30 at 5 3A00 p m ET 2823 3A00 CET 29 50515 2Air Force Chief Master Sergeant Rod McKinley 28U S Air Force Retired 29 Joins MicroTech as Vice President of Strategic Partnerships 12870 1Air Force Chief Master Sergeant Rod McKinley 28U S Air Force Retired 29 Joins MicroTech as Vice President of Strategic Partnerships 12870 2Air Force Chief Master Sergeant Rod McKinley 28U S Air Force Retired 29 Joins MicroTech as Vice President of Strategic Partnerships 12870 3
...um: The Takeda Oncology,Company today reported upd...ed Phase III clinical trials of VELCADE based comb...-eligible patients with previously untreated,multi...val (PFS) was observed,in one study comparing VELC...mycin and dexamethasone (VAD), as well as in anoth...
...sts that ofatumumab has activity in heavily pre-tr... , , , PHILADELPHIA, Dec. 8 GlaxoSmithKli... positive results from a pivotal trial pre-planned...he treatment of refractory chronic lymphocytic leu... of ofatumumab for heavily pre-treated patients wi...
Other Medicine Technology:Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 2Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 3Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 4Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 5Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 6Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9
(Date:11/21/2009)... HAPPYneuron,s most popular and addictive...and iPod Touch. , Mountai...n,s most popular and addictive game, SplitWords, i...t Words is designed to help banish that ,tip of th...Phone brain game challenges the brain by encourag...
(Date:11/21/2009)... Linwood Group ask whether there is a sec...red? , London, UK (PRWEB)...th up to one in three of the adult UK population d...ing alcohol-related liver disease*, it is hardly a...habilitation programmes and residential centres fo...
(Date:11/20/2009)...HINGTON, Nov. 20 The A... to modify health care reform legislation released...a health insurance individual coverage mandate. Th... mandate will minimize adverse selection stemming ...ribed by the bill. ,, "The individual mandate l...
(Date:11/20/2009)... Senators and Congressmen in Competitive ... Health Care Vote , Washi...d congressmen running for re-election next year in...Charlie Cook, may come to regret voting for House ...ording to a breaking Zogby International/ O’...
(Date:11/20/2009).... LOUIS, Nov. 20 Cente... it will present at the Bank of America Merrill Ly...3, 2009, at the Crowne Plaza Hotel Times Square in...ay, December 2nd at 8:30 a.m. Eastern Time. Invest..., audio webcast of Centene,s presentation at: htt...
Breaking Medicine News(10 mins):Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3
... Applicants for Social Security Di...y; Allsup Answers Common Benefits Questions , ..., 2008 -- People who find themselves with a mental... about a person’s life changes, the past sti...
... Central Bucks Specialists, a lead...s MxSecure, Inc., the nation's leading provid... clinics, as their outsourced medical transcriptio...n's leading provider of medical transcription...
...ne of few trials to recruit large percentage of Af...ipants, PORTLAND, Ore., July 8 Keeping a food di... a study from Kaiser Permanente,s Center,for Healt...ssue of the American Journal of Preventive Medicin...
...ILLS, Calif., July 7 "For several months,senior l...orking on a,settlement agreement with the Californ...ure to all issues relating to previous rescissions...,review our proposal., Following are the key elem...
...uly 7 Ventas, Inc. (NYSE: VTR ),("Ventas" or the... 2008,second quarter earnings release after the cl...ence call to discuss those earnings will be held o...any,s website at http://www.ventasreit.com or at...
... Ill., July 7 The University HealthSystem,Consort... newly created,position of Chief Learning Officer....e in academic internal medicine and comes to UHC f...ingleton was the Petersdorf Scholar in Residence a...
Other Medicine News:Health News:Past Earnings Play Role in Determining SSDI Benefits 2Health News:Past Earnings Play Role in Determining SSDI Benefits 3Health News:Past Earnings Play Role in Determining SSDI Benefits 4Health News:Past Earnings Play Role in Determining SSDI Benefits 5Health News:Central Bucks Specialists, a Cardiology and Gastroenterology Multi-location Clinic, Selects MxSecure, Inc., Provider of Medical Transcription Services, as their Transcription Provider. 2Health News:Central Bucks Specialists, a Cardiology and Gastroenterology Multi-location Clinic, Selects MxSecure, Inc., Provider of Medical Transcription Services, as their Transcription Provider. 3Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 2Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 3Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 4Health News:Anthem Blue Cross Statement on Settlement Discussions with the California Department of Managed Health Care 2Health News:University HealthSystem Consortium Names Susan K. Pingleton, MD, as Its Chief Learning Officer 2
...pose agarose, has been developed for analytical an... separation of high molecular weight DNA [pulsed-f...high gel strength agarose ( 1800 g/cm2, 1%). T...trations of agarose in electrophoretic gels. The a...
Agarose, high gel strength, Molecular Biology Grade
UltraClean™ Forensic Agarose
...se 1000 is specifically formulated for high resolu...This standard melting temperature agarose can reso...ce in size. UltraPure™ Agarose 1000 gels ex...nd improved clarity for enhanced visibility of fra...
Medicine Products: